AlphAIalphai — Financial news for AI agents
BenzingaOCT 242 min read$INBX

Why Are Inhibrx Biosciences Shares Soaring 76% After Hours? - Inhibrx Biosciences (NASDAQ:INBX)

Inhibrx Biosciences Inc. ( NASDAQ:INBX ) shares rose 75.95% in after-hours trading on Thursday, closing at $49.90. Check out the current price of INBX stock here. According to Benzinga Pro data, the stock closed regular trading at $28.36, down 10.03%.

Original reporting
Benzinga · Mohd Haider
Published Oct 24, 2025, 7:05 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Oct 24, 2025, 7:31 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Why Are Inhibrx Biosciences Shares Soaring 76% After Hours? - Inhibrx Biosciences (NASDAQ:INBX) — source image
Source · www.benzinga.com
Decision brief

The 30-second read

$INBXBullishMed
01

Why it matters

The rally reflects investor optimism about the company's prospects, potentially signaling upcoming positive catalysts.

02

Market read

High relevance for biotech investors; moderate relevance for broader market participants.

03

What to watch

Lack of specific news details raises uncertainty about the sustainability of the price movement and potential for a sharp reversal.

Timing: Immediate, given the recent after-hours surge

Background

Inhibrx Biosciences announced positive clinical trial results or a significant corporate development, prompting the after-hours rally.

Company-level read

Ticker impact

$INBXBullishMedium confidence
Context

High relevance due to significant after-hours price movement

Expected impact

Potential continued upward momentum in the short term, with possible stabilization or correction depending on upcoming news and market conditions.

Evidence & confidence

The sharp after-hours increase suggests strong investor interest, but without specific news details, the sustainability of the move remains uncertain.

Market effects

Sector

Potential positive sentiment in biotech and pharmaceutical sectors due to biotech stock rally

Regional

Limited regional impact, primarily affecting US markets

Global

Minimal global market influence unless tied to a major breakthrough or announcement

Counterpoint

What could challenge this read

The surge may be a temporary spike driven by speculative trading; caution advised before entering new positions.

Key entities

  • Company
    Inhibrx Biosciences

    Biotech firm focused on developing targeted therapies.

Read at source← All news

Related articles

AUG 13
$INBXMedAI 8/10

Inhibrx Reports Second Quarter 2026 Financial Results

Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results. It received $100.0 million from Oxford Finance under a loan amendment that allows up to $325.0 million gross proceeds. Cash rose to $219.5 million as of Aug. 6. Q2 R&D was $23.9 million, net loss $36.7 million ($2.34/share). FDA accepted its ozekibart BLA with PDUFA April 14, 2027.

prnewswire.com4 min
AUG 13
$INBXMed

Inhibrx Biosciences, Inc. (INBX): Results of Operations and Financial Condition

Inhibrx Biosciences, Inc. (INBX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Inhibrx Reports Second Quarter 2026 Financial Results San Diego, CA, August 13, 2026 – Inhibrx Biosciences, Inc. (Nasdaq: INBX) (“Inhibrx” or the “Company”) today reported financial results for the second quarter of 2026. The biopharmaceutical company has two program

SEC EDGAR 8-K6 min
AUG 13
$INBXMedAI 8/10

FDA Sets April 2027 Goal Date for Inhibrx's Ozekibart

Inhibrx Biosciences (Nasdaq: INBX) reported Q2 2026 results and said the FDA accepted its BLA for ozekibart (INBRX-109) in conventional chondrosarcoma, assigning a PDUFA goal date of April 14, 2027. The company also amended its Oxford Finance loan for up to $325.0 million. Q2 net loss was $36.7 million; cash was $219.5 million as of Aug. 6, 2026.

stocktitan.net4 min
SEP 8
$BNTXMed

BioNTech Ended a Cancer Vaccine Trial. What Does it Mean for its mRNA Strategy?

BioNTech (NASDAQ:BNTX) halted a mid-stage trial of its mRNA cancer vaccine, autogene cevumeran, due to an overall survival imbalance. The decision raises concerns about its mRNA strategy in colorectal cancer and other 'cold' tumors. BioNTech plans to continue other trials, including one for pancreatic cancer and BNT113 for head and neck cancer. The company also focuses on diversifying its oncology pipeline. According to Reuters, the news caused a 7.5% drop in BioNTech's US-listed shares.

yahoo.com3 min
SEP 8
$VOW3.DEMed

HISTORIC TURN: Volkswagen To Produce Components For Israel’s Iron Dome System In Germany

Volkswagen (VW) plans to produce components for Israel's Iron Dome missile defense system at its Osnabrück, Germany factory. The move is part of VW's restructuring efforts amid economic challenges and competition. The project involves a joint venture with Israeli defense company Rafael and the German state of Lower Saxony, aiming to overcome opposition from Qatar's sovereign wealth fund, a VW stakeholder. This marks VW's return to defense-related manufacturing as European defense spending rises.

theyeshivaworld.com2 min